InflaRx N.V. (IFRX)
| Previous close | 1.7800 |
| Open | 1.8800 |
| Bid | 1.8900 x 1200 |
| Ask | 1.9200 x 1200 |
| Day's range | 1.7300 - 1.9200 |
| 52-week range | 0.7760 - 3.2800 |
| Volume | |
| Avg. volume | 76,027 |
| Market cap | 84.871M |
| Beta (5Y monthly) | 0.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5100 |
| Earnings date | 05 May 2023 - 09 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.00 |
- GlobeNewswire
InflaRx Reports Full Year 2022 Financial and Operating Results
Major progress in development of vilobelimab Phase III study in PG announced following detailed feedback and recommendations from the U.S. Food and Drug Administration (FDA); clinical trial protocol submitted; first patient expected around mid-2023Fast Track and Orphan Drug designations granted for treatment of pyoderma gangrenosum (PG) in the United States and Orphan Drug designation granted in Europe Encouraging results from Phase III study in critically ill COVID-19 patients published in The
- GlobeNewswire
InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients
Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG) Trial size to be adapted upon interim analysis with planned total patient number between approximately 50 and 100 patientsFDA review of application for emergency use authorization (EUA) of vilobelimab for the treatment of critically ill COVID-19 patients ongoing InflaRx’s management team to host investor and business meetings during JPM Week, January 9 – 12, 2023 in San Franci
- GlobeNewswire
InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19
InflaRx will provide access to certain clinical, manufacturing and regulatory documentation for vilobelimab to facilitate STS’s regulatory filings in ChinaSTS plans to request regulatory approval in China for its own anti-C5a-antibody BDB-001 for the treatment of COVID-19 based on InflaRx’s technology in-licensed by STSInflaRx will receive 10% royalties on net sales of BDB-001 for the treatment of COVID-19 in ChinaSTS to make an additional USD 2.5 million investment in InflaRx at a price of USD
